Fig. 2.
Fig. 2. CTL activity against peptide-pulsed and mHag-positive target cells by ex vivo–induced HA-1– and HA-2–specific CTLs. HA-1 CTLs no. 1, 2, 3, and 4 and HA-2 CTLs no. 1 and 2 were generated from different individuals using PBDC (HA-1 CTLs no. 1, 4 and HA-2 CTLs no. 1, 2) or BMDC (HA-1 CTLs no. 2, 3). The cytotoxic activities of in vivo–induced HA-1– and HA-2–specific CTLs against the same target cells are shown as comparison. Target cells: autologous PHA-blasts (◊); autologous PHA-blasts pulsed with peptide (⧫; EBV-LCL positive for HA-1 (n = 4) or HA-2 (n = 3) (▧); EBV-LCL negative for HA-1 (n = 3) or HA-2 (n = 3) (◍); HA-1– or HA-2–negative EBV-LCL pulsed with HA-1 or HA-2 peptide (◍).

CTL activity against peptide-pulsed and mHag-positive target cells by ex vivo–induced HA-1– and HA-2–specific CTLs. HA-1 CTLs no. 1, 2, 3, and 4 and HA-2 CTLs no. 1 and 2 were generated from different individuals using PBDC (HA-1 CTLs no. 1, 4 and HA-2 CTLs no. 1, 2) or BMDC (HA-1 CTLs no. 2, 3). The cytotoxic activities of in vivo–induced HA-1– and HA-2–specific CTLs against the same target cells are shown as comparison. Target cells: autologous PHA-blasts (◊); autologous PHA-blasts pulsed with peptide (⧫; EBV-LCL positive for HA-1 (n = 4) or HA-2 (n = 3) (▧); EBV-LCL negative for HA-1 (n = 3) or HA-2 (n = 3) (◍); HA-1– or HA-2–negative EBV-LCL pulsed with HA-1 or HA-2 peptide (◍).

Close Modal

or Create an Account

Close Modal
Close Modal